Most HIV vaccines in development are designed to protect people against infection. However, a vaccine in development in Antwerp is focusing on harnessing individuals' own immune systems to target and
The FDA has granted University of Western Ontario researchers approval to start human trials of their HIV vaccine. Even though Dr. Chil-Yong Kang and his team trail others in their field who have...
University of Toronto researchers surveyed people at risk of contracting HIV and found that misconceptions about the safety of HIV vaccine trials are slowing research efforts. Along with a general...
When scientists first started using cyclodextrin in meds as an emulsifier and cinical trials as a control, there were no therapeutic benefit. But after one trial showed the drug could be a therapy
Could HIV one day be treated as nothing more than a minor infection? That's what researchers at the National Biotech Center in Madrid are hoping to eventually achieve with MVA-B, their early-stage
Researchers at the Imperial College London and Johns Hopkins University have discovered a new method that prevents HIV from weakening a patient's immune system. According to their research, the
Norwegian biotech Bionor Pharma has released results from a study of its therapeutic HIV vaccine, Vacc-4x. After initially planning to shelve the vaccine last October, the company is now plotting
By focusing on HIV's envelope protein and targeting immature B cells--which the virus homes in on--researchers have found a new approach for potential vax candidates. The researchers--from Duke
The National Institutes of Health has awarded Emory University a $26 million grant for its work on HIV/AIDS vaccines. The university will work to develop a vaccine in the next 5 years with the help
Blue Bell, PA-based Inovio Pharmaceuticals has published data from two preclinical HIV trials this week. The results, published in Vaccine and PLoS One respectively, demonstrated the vaccines'